Zealand launches second late-stage study of dasiglucagon for severe diabetic hypoglycemia

|About: Zealand Pharma (ZEAL)|By:, SA News Editor

Zealand Pharma A/S (ZEAL +0.3%) initiates a second Phase 3 clinical trial assessing soluble glucagon analog dasiglucagon for the rescue treatment of severe hypoglycemia (low blood sugar) in type 1 diabetics.

The study's objective is to confirm rapid plasma glucose increase after a single administration of dasiglucagon in T1D patients with insulin-induced hypoglycemia.

The first Phase 3 was launched in July with enrollment completed in October. Topline results should be available in Q2 2018.

Dasiglucagon has Orphan Drug status for the indication in the U.S. and Europe.